Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) from a buy rating to a strong-buy rating in a report published on Sunday morning.

Several other brokerages also recently issued reports on KNSA. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. Wells Fargo & Company raised their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, July 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Buy” and an average price target of $41.17.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $36.86 on Friday. The business has a fifty day simple moving average of $31.32 and a two-hundred day simple moving average of $26.77. Kiniksa Pharmaceuticals International has a 1 year low of $17.82 and a 1 year high of $36.93. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of 921.73 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total value of $4,601,984.80. Following the transaction, the chief operating officer owned 49,915 shares in the company, valued at $1,657,178. The trade was a 73.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Michael R. Megna sold 17,000 shares of the business’s stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $32.35, for a total value of $549,950.00. Following the sale, the chief accounting officer owned 33,041 shares in the company, valued at approximately $1,068,876.35. This trade represents a 33.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 562,271 shares of company stock valued at $18,716,309. Company insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rubric Capital Management LP lifted its stake in shares of Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares during the period. Vanguard Group Inc. lifted its stake in Kiniksa Pharmaceuticals International by 4.7% in the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after buying an additional 151,604 shares during the period. Acadian Asset Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 22.6% in the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock valued at $35,067,000 after buying an additional 233,668 shares during the period. Qube Research & Technologies Ltd lifted its stake in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the period. Finally, Millennium Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares during the period. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.